AscellaHealth highlights value of HUB partnership with Abeona Therapeutics

AscellaHealth highlights the value of its HUB partnership with Abeona Therapeutics (ABEO) in the pre-and-post launch commercialization of ZEVASKYN, an FDA-approved cell-based gene therapy. Working as a collaborative partner, AscellaHealth designed and executed patient-centric, end-to-end solutions to address unique clinical, operational and reimbursement needs for a new-to-world autologous cell-based gene therapy. By focusing on the requirements of patients throughout the entire therapeutic journey, AscellaHealth led the collaborative effort to build and launch AbeonaAssist, a highly customized patient support program that creates a seamless experience for patients, caregivers and healthcare providers. “Abeona’s groundbreaking cell-based gene therapy demanded a HUB partner who could build tailored infrastructure from the ground up,” said William White, Vice President of Market Access at Abeona Therapeutics. “AscellaHealth’s comprehensive expertise in navigating this complex journey, from patient and provider engagement to optimizing reimbursement for this first-of-its-kind treatment, made them the unequivocal partner of choice. Since launch, their unwavering commitment to a patient-centric model, which perfectly aligns with our program’s vision, has proven invaluable.”